Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.

Next Previous
X
Search
Trial Profile

Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Proof of concept
  • Sponsors INmune Bio

    • Most Recent Events

    • 02 Aug 2024 According to an INmune Bio media release, New Phase 1b analysis of proteomic data presented at AAIC.
    • 29 Jul 2024 According to an INmune Bio media release, results from this trial will be presented at the annual Alzheimer's Association International Conference (AAIC) in Philadelphia, PA.
    • 30 Apr 2024 According to an INmune Bio media release, company share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimers Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top